» Articles » PMID: 34479944

Elucidating the Motif for CpG Oligonucleotide Binding to the Dendritic Cell Receptor DEC-205 Leads to Improved Adjuvants for Liver-Resident Memory

Abstract

DEC-205 is a cell-surface receptor that transports bound ligands into the endocytic pathway for degradation or release within lysosomal endosomes. This receptor has been reported to bind a number of ligands, including keratin, and some classes of CpG oligodeoxynucleotides (ODN). In this study, we explore in detail the requirements for binding ODNs, revealing that DEC-205 efficiently binds single-stranded, phosphorothioated ODN of ≥14 bases, with preference for the DNA base thymidine, but with no requirement for a CpG motif. DEC-205 fails to bind double-stranded phosphodiester ODN, and thus does not bind the natural type of DNA found in mammals. The ODN binding preferences of DEC-205 result in strong binding of B class ODN, moderate binding to C class ODN, minimal binding to P class ODN, and no binding to A class ODN. Consistent with DEC-205 binding capacity, induction of serum IL-12p70 or activation of B cells by each class of ODN correlated with DEC-205 dependence in mice. Thus, the greater the DEC-205 binding capacity, the greater the dependence on DEC-205 for optimal responses. Finally, by covalently linking a B class ODN that efficiently binds DEC-205, to a P class ODN that shows poor binding, we improved DEC-205 binding and increased adjuvancy of the hybrid ODN. The hybrid ODN efficiently enhanced induction of effector CD8 T cells in a DEC-205-dependent manner. Furthermore, the hybrid ODN induced robust memory responses, and was particularly effective at promoting the development of liver tissue-resident memory T cells.

Citing Articles

Engineering PEG10assembled endogenous virus-like particles with genetically encoded neoantigen peptides for cancer vaccination.

Tang R, Guo L, Wei T, Chen T, Yang H, Ye H Elife. 2024; 13.

PMID: 39269893 PMC: 11398863. DOI: 10.7554/eLife.98579.


Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design.

Clemente B, Denis M, Silveira C, Schiavetti F, Brazzoli M, Stranges D Front Immunol. 2023; 14:1294929.

PMID: 38090568 PMC: 10711611. DOI: 10.3389/fimmu.2023.1294929.


Elucidation of the role of nucleolin as a cell surface receptor for nucleic acid-based adjuvants.

Kitagawa S, Matsuda T, Washizaki A, Murakami H, Yamamoto T, Yoshioka Y NPJ Vaccines. 2022; 7(1):115.

PMID: 36202858 PMC: 9537314. DOI: 10.1038/s41541-022-00541-6.